News
![Helping to support momentum on antimicrobial innovation](https://pharmaphorum.com/wp-content/uploads/2020/11/Helping-to-support-momentum-on-antimicrobial-innovation.jpg)
Undeterred by FDA setback, GSK snaps up Spero antibiotic
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults